- Home
- PLBC vs EBS Comparison
PLBC vs EBS Comparison
Compare PLBC & EBS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PLBC | EBS |
|---|---|---|
| Founded | 1980 | 1998 |
| Country | United States | United States |
| Employees | 197 | N/A |
| Industry | Finance Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 316.6M | 625.0M |
| IPO Year | 2005 | 2006 |
Fundamental Metrics
Financial Performance| Metric | PLBC | EBS |
|---|---|---|
| Price | $45.70 | $12.33 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 1 |
| Target Price | ★ $55.00 | $15.00 |
| AVG Volume (30 Days) | 17.9K | ★ 848.8K |
| Earning Date | 01-14-2026 | 10-29-2025 |
| Dividend Yield | ★ 2.64% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 4.23 | 1.35 |
| Revenue | $89,868,000.00 | ★ $788,900,000.00 |
| Revenue This Year | $21.11 | N/A |
| Revenue Next Year | $16.11 | $15.21 |
| P/E Ratio | $10.77 | ★ $8.45 |
| Revenue Growth | ★ 12.51 | N/A |
| 52 Week Low | $38.71 | $4.02 |
| 52 Week High | $49.63 | $13.41 |
Technical Indicators
Market Signals| Indicator | PLBC | EBS |
|---|---|---|
| Relative Strength Index (RSI) | 71.32 | 64.02 |
| Support Level | $43.50 | $11.34 |
| Resistance Level | $45.71 | $12.28 |
| Average True Range (ATR) | 0.81 | 0.50 |
| MACD | 0.24 | 0.05 |
| Stochastic Oscillator | 85.11 | 97.18 |
Price Performance
Historical ComparisonAbout PLBC Plumas Bancorp
Plumas Bancorp provides various banking products and services in Northeastern California and Northwestern Nevada. It provides various deposit products such as checking, interest-bearing checking, business sweep, public funds sweep, savings, time deposit, and retirement accounts. The bank's loan portfolio consists of commercial real estate loans; commercial and industrial loans; consumer loans; agricultural loans; residential real estate loans, and construction and land development loans. The bank generates revenue from loans and investment securities in its portfolio and, to a lesser extent, service fees.
About EBS Emergent Biosolutions Inc.
Emergent BioSolutions Inc offers public health products to the government and healthcare providers. Company operates in three segments namely Commercial Product, MCM Products, and Services segment. The Commercial Product Segment consisting of Nasal Spray; the MCM Products Segment consisting of Anthrax-MCM products, Smallpox-MCM products and Other Products and the Services Segment consisting of Bioservices portfolio. The key revenue is generated through the commercial segment which consists of NARCAN and other commercial products.